P.P.M. Kooij

Treatment With the Radiolabeled Somatostatin Analog [ ¹⁷⁷ Lu-DOTA ⁰ ,Tyr ³ ]Octreotate: Toxicity, Efficacy, and Survival

Dik J. Kwekkeboom, Wouter W. de Herder, Boen L.R. Kam et al. · Journal of Clinical Oncology · 2008 · 1.4K citations · Full text

Medicine, Nuclear Medicine, Oncology +17

Radiolabeled Somatostatin Analog [¹⁷⁷Lu-DOTA⁰,Tyr³]Octreotate in Patients With Endocrine Gastroenteropancreatic Tumors

Dik J. Kwekkeboom, Jaap J.M. Teunissen, Willem H. Bakker et al. · Journal of Clinical Oncology · 2005 · 659 citations · Full text

Medicine, Oncology, Pharmacology +15

LOCALISATION OF ENDOCRINE-RELATED TUMOURS WITH RADIOIODINATED ANALOGUE OF SOMATOSTATIN

E. P. Krenning, Wout A. P. Breeman, P.P.M. Kooij et al. · The Lancet · 1989 · 622 citations

Medicine, Endocrinology, Oncology +10

[177Lu-DOTA0,Tyr3]octreotate: comparison with [111In-DTPA0]octreotide in patients

Dik J. Kwekkeboom, Willem H. Bakker, P.P.M. Kooij et al. · European Journal of Nuclear Medicine and Molecular Imaging · 2001 · 471 citations

Medicine, Endocrinology, Nuclear Medicine +3

Phase I study of peptide receptor radionuclide therapy with [111In-DTPA0]octreotide: The rotterdam experience

Roelf Valkema, Marion de Jong, Willem H. Bakker et al. · Seminars in Nuclear Medicine · 2002 · 433 citations

Medicine, Nuclear Medicine, Oncology +14